Century Therapeutics, Inc. IPSC
We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. As a result, we believe such "off-the-shelf" therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population. What we believe further sets us apart from other allogeneic approaches is our focus on induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and differentiate into any cell type, enabling virtually unlimited genetic editing, consistent reproducibility, and scalable manufacturing. We have created a comprehensive, genetically engineered allogeneic cell therapy platform that includes:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — | — | — |
| R&D | — | — | — | — | $75.6M | $39.7M | — |
| SG&A | $24.0M | $33.2M | $34.7M | $31.9M | $19.2M | $9.5M | — |
| Total operating expenses | $126.4M | $144.7M | $148.8M | $139.0M | $94.9M | $53.9M | — |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M | -$53.9M | — |
| Interest expense | — | — | $540.0K | $1.0M | $1.3M | $381.0K | — |
| Pre-tax income | -$9.6M | -$124.8M | -$134.8M | -$130.8M | -$95.8M | -$53.6M | — |
| Income tax | $68.0K | $1.8M | $1.9M | $91.0K | $43.0K | — | — |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M | -$53.6M | — |
| EPS, basic | -0.14 | -1.61 | -2.30 | -2.27 | -2.96 | -7.16 | — |
| EPS, diluted | -0.14 | -1.61 | -2.30 | -2.96 | -2.96 | -7.16 | — |
| Shares, diluted (wtd. avg.) | 86.6M | 78.6M | 59.3M | 32.4M | 32.4M | 7.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.9M | $58.4M | $49.3M | $86.2M | $58.2M | $27.7M | $44.1M |
| Short-term investments | $55.3M | $130.9M | $125.4M | $231.2M | $166.4M | $48.5M | — |
| Total current assets | $120.8M | $194.1M | $177.0M | $319.7M | $228.2M | $78.8M | — |
| Property, plant and equipment | $50.0M | $62.1M | $71.7M | $82.8M | $58.0M | $15.4M | — |
| Other intangibles | $34.2M | $34.2M | — | — | — | — | — |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M | $106.8M | — |
| Accounts payable | $4.8M | $3.1M | $2.7M | $5.5M | $7.6M | $8.1M | — |
| Total current liabilities | $20.2M | $129.8M | $17.8M | $29.8M | $15.7M | $12.1M | — |
| Long-term debt | — | — | — | $3.7M | $8.9M | $9.6M | — |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M | $33.4M | — |
| Retained earnings | -$791.9M | -$782.3M | -$655.8M | -$519.1M | -$388.2M | -$292.3M | — |
| Total equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M | -$106.4M | -$91.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M | -$41.3M | — |
| Depreciation and amortisation | $13.1M | $13.3M | $13.0M | $8.4M | $3.7M | $1.4M | — |
| Stock-based compensation | $6.8M | $12.7M | $14.6M | $10.7M | $4.7M | $876.0K | — |
| Capital expenditure | $848.0K | $154.0K | $13.7M | $30.6M | $45.0M | $9.8M | — |
| Investing cash flow | $107.5M | $47.5M | $61.1M | -$13.1M | -$298.3M | -$22.8M | — |
| Financing cash flow | $173.0K | $74.6M | -$9.7M | $27.2M | $417.8M | $47.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-026759.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $5.2M | $2.2M | $6.6M | $109.2M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$53.6M | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |